Loading clinical trials...

Reducing Dementia Risk With Digital Health Coaching | Clinical Trials | Clareo Health

UNKNOWNNA

Reducing Dementia Risk With Digital Health Coaching

Digital Cognitive Multidomain Alzheimer's Risk Velocity Study (DC-MARVEL)

NCT04559789•Neurotrack Technologies, Inc.

Summary

The Digital Cognitive Multi-domain Alzheimer's Risk Velocity (DC MARVEL) study is a 2-year randomized controlled trial on dementia prevention. The purpose of this study is to determine the effect of a digital cognitive health program on dementia risk, cognitive function, and general health outcomes in middle age to older adults compared to a control group that receives health education.

Detailed Description

Alzheimer's Disease (AD) is expected to affect 131 million people worldwide by 2050, but as many as 40% of these cases may be prevented by targeting modifiable risk factors such as diet, physical activity, cognitive engagement, and smoking. Neurotrack Technologies, Inc. will test the efficacy of a digital multi-domain lifestyle intervention with health coaching for cognitive health designed to change behaviors associated with increased risk for AD. This digital intervention addresses the challenge of scaling effective multi-domain lifestyle interventions for cognitive health and has the potential to improve risk behaviors, thereby reducing and/or delaying cognitive decline in older adults at risk for AD.

Eligibility

Age

45 - 75 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Age 45-75
•BMI 18.5 - 39.9 kg/m2
•Fluent in English (written and spoken)
•A minimum of 2 of the following risk factors for AD from ANU-ADRI: High school education or less; Overweight, or class I or class II obese (BMI 25-39.9 kg/m2); History of diabetes; History of hypertension; History of high cholesterol; History of smoking; History of traumatic brain injury
•Maximum of 1 of the following protective factors for AD from ANU-ADRI: High level of physical activity; High fish consumption; High level of cognitive engagement
•Ability to send and receive text messages
•Own a smartphone, have a reliable internet connection, and willing to use email
•Ability to participate in light to moderate physical activity
•Willingness to be randomized

Exclusion Criteria

•Physician diagnosis of: mental health condition (e.g., eating disorder, alcohol/substance use, schizophrenia, etc.); neurologic conditions (e.g. epilepsy, stroke, multiple sclerosis, Parkinson's disease, brain tumor, or severe traumatic brain injury); dementia, probable dementia, or mild cognitive impairment; other significant health condition (e.g. congestive heart failure, chronic obstructive pulmonary disease, coronary artery disease, renal failure, chronic kidney disease, pulmonary hypertension)
•Recent cardiovascular event or recent treatment for cancer (within the last year); on dialysis; or on active organ transplant list
•Visual problems that prevent viewing screen at a normal distance (e.g., legal blindness, detached retina, occlusive cataracts)
•History of learning disability
•Currently participating in a formal cognitive training coaching program or other lifestyle change program (e.g. diabetes prevention program)
•Currently pregnant or planning on becoming pregnant in the next two years

Locations (1)

University of Arkansas

Fayetteville, Arkansas, United States

Key Dates

Start Date

January 4, 2021

Primary Completion Date

January 30, 2024

Completion Date

January 30, 2024

Last Updated

August 31, 2021

Enrollment

200

ACTUAL participants

Conditions

Alzheimer DiseaseDementiaMild Cognitive ImpairmentCognitive Decline

Interventions

MindMate + Health Coaching

BEHAVIORAL

Health Education

OTHER

Sense4Safety Intervention

NCT07220668

Mild Cognitive Impairment

View study

RECRUITINGPHASE1

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

View study

RECRUITINGEARLY_PHASE1

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 31, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Reducing Dementia Risk With Digital Health Coaching

Inclusion Criteria

Exclusion Criteria

Sense4Safety Intervention

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)